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1. Introduction 
1.1 Cathepsins 
Cathepsins, originally identified as lysosomal proteases, play a fundamental role in 
intracellular protein turnover in lysosomes. However, several cathepsins and variants of 
cathepsins can also be found on the cell membrane, in the cytosol, nucleus, mitochondria, and 
extracellular space. These cathepsins are involved in a variety of important physiological and 
pathological processes [reviewed in: (Brix et al., 2008; Frlan and Gobec, 2006; Lutgens et al., 
2007; Mohamed and Sloane, 2006; Nomura and Katunuma, 2005; Obermajer et al., 2008; Reiser 
et al., 2010; Stoka et al., 2005; Turk et al., 2001; Vasiljeva et al., 2007; Victor and Sloane, 2007)]. 
Cathepsins are classified mechanistically into groups which include serine (cathepsins A and 
G), aspartic (cathepsins D and E), and cysteine cathepsins (cathepsins B, C, F, H, L, K, O, S, V, 
W, and X). This classification is based on the nucleophilic residues present on their active sites 
responsible for proteolytic cleavage (Rawlings et al., 2006; Turk et al., 2001).   
Cathepsins are synthesized as zymogens composed of a signal peptide, a propeptide, and 
mature protein of distinct length and substrate specificity for individual cathepsins 
(Rawlings et al., 2006). The signal peptide is cleaved in the Endoplasmic Reticulum and the 
pro-protein is activated by proteolytic removal of the N-terminal pro-peptide either by 
autocatalysis in acidic environments, or by other proteases. The pro-peptide region of the 
cathepsin plays multiple roles. It can act as an inhibitor to block access to the active site that 
regulates cathepsin activity. In addition the propeptide can act as an intramolecular 
chaperone that assists in protein folding, or as a trafficking signal that targets the protein to 
its destination (Turk et al., 2002). Cathepsins exhibit a broad range of functions and tissue 
expression (Brix et al., 2008; Turk et al., 2001). Some of the cathepsins are ubiquitously 
expressed and others are tissue or cell-type specific. 
Cathepsins have been shown to be involved in the process of tumor invasion and metastasis 
(Białas and Kafarski, 2009; Lindeman et al., 2004; Nomura and Katunuma, 2005; Obermajer 
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et al., 2008) and have been linked to many types of cancer including melanoma (Matarrese et 
al., 2010; Quintanilla-Dieck et al., 2008), hepatocellular carcinoma (Leto et al., 1997; Leto et 
al., 1996), breast cancer (Foekens et al., 1998; Laurent-Matha et al., 1998; Masson et al., 2011; 
Vashishta et al., 2007), lung cancer (Ledakis et al., 1996; Schweiger et al., 2000), prostate 
cancer (Brubaker et al., 2003; Kishore Kumar et al., 2010; Podgorski et al., 2009; Podgorski et 
al., 2007; Steffan et al., 2010), nasopharyngeal cancer (Cheng et al., 2008; Xu et al., 2009), 
thyroid cancer (Mikosch et al., 2008; Tedelind et al., 2010), bone cancer (Podgorski et al., 
2009; Podgorski et al., 2007) as well as osteoporosis (Bone et al., 2010; Deal, 2009; Stoch and 
Wagner, 2007; Yasuda et al., 2005), rheumatoid arthritis (Skoumal et al., 2005; Skoumal et al., 
2008), Alzheimer’s Disease (Hook et al., 2007; Hook et al., 2009; Urbanelli et al., 2008), 
cardiovascular disease (Bengtsson et al., 2008; Lutgens et al., 2007), and obesity (Li et al., 
2010; Naour et al., 2010; Podgorski et al., 2007; Yang et al., 2008).  
1.2 Cysteine cathepsins 
Cysteine cathepsins belong to papain-like enzyme family sharing similar amino acid 
sequences and tertiary structures (Turk et al., 2001). Eleven cysteine cathepsins B, C, F, H, L, 
K, O, S, V, W, and X have been identified in the human genome (Turk et al., 2001). Cysteine 
cathepsins have been documented to play a vital role in a variety of biological processes and 
pathological processes (Brix et al., 2008; Joyce et al., 2004; Lecaille et al., 2002; Obermajer et 
al., 2008; Reiser et al., 2010; Stoka et al., 2005; Turk et al., 2001; Victor and Sloane, 2007). The 
correct sorting and trafficking of the members of cysteine cathepsins are critical in their 
proteolytic actions to maintain homeostasis (Brix et al., 2008). The dysregulation of protease 
activity has resulted in numerous pathologies. Several cysteine cathepsins have been 
recognized as relevant drug targets in the development of many disease therapies (Deal, 
2009; Le Gall et al., 2008; Mohamed and Sloane, 2006; Podgorski, 2009; Turk, 2006; Vasiljeva 
et al., 2007). 
1.2.1 Cathepsin B and K 
Human cathepsin B precursor is a protein of 339 amino acids that consists of a signal 
peptide at amino-terminal end of 17 amino acids (1-17). The proprotein is then activated as a 
single-chain form of 254 amino acids (80-333) or double-chain form of 47 amino acids (80-
126) and 205 amino acids (129-333) (Pungerčar et al., 2009; Rozman et al., 1999). Unlike other 
cysteine proteases cathepsin B is unique due to its ability to act both as an endopeptidase 
and a peptidyldipeptidase. It contains a unique occluding loop which is characterized by 
two adjacent histidine residues (His 110 and His 111) and are responsible for the 
dipeptidityl carboxypeptidase activity (Illy et al., 1997). Cathepsin B is the most abundant in 
all of the cysteine proteases (Kirschke et al., 1995). 
Cathepsin B participates in many diverse cellular processes including protein degradation, 
antigen processing (Zhang et al., 2000), and apoptosis (Bien et al., 2010; Chwieralski et al., 2006; 
Roberts et al., 1999). It has been implicated in a variety of diseases including cancer invasion 
and metastasis (Ledakis et al., 1996; Matarrese et al., 2010; Roshy et al., 2003; Sinha et al., 2001; 
Szpaderska and Frankfater, 2001; Yan et al., 1998), angiogenesis (Im et al., 2005; Kruszewski et 
al., 2004; Malla et al., 2011; Sinha et al., 1995), inflammation (Hashimoto et al., 2001; Kakegawa 
et al., 2004), and Alzheimer’s Disease (Gan et al., 2004; Hook, 2006; Hook et al., 2008). Thus, 
cathepsin B is a promising target for anti-cancer drug design (Lim et al., 2004; Palermo and 
Joyce, 2008) and a potential target for Alzheimer’s Disease (Hook et al., 2008). 
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Human cathepsin K precursor is a protein of 329 amino acids that consists of an amino-
terminal signal peptide of 15 amino acids (1-15), a propeptide of 99 amino acids (16-114), 
and a catalytic region of 215 amino acids (115-329) (Lecaille et al., 2008).  
Cathepsin K is highly expressed in osteoclasts (Drake et al., 1996) but also occurs in lung 
epithelia cells (Bühling et al., 1999), cultured primary neonatal skin fibroblasts activated 
chondrocytes, and in synovial fibroblasts of patients suffering from rheumatoid arthritis 
(Lecaille et al., 2008; Ruettger et al., 2008; Skoumal et al., 2005). Because of its strong 
collagenolytic activity cathepsin K has been described as the major enzyme responsible for 
the degradation of organic bone matrix, and is believed to play a fundamental role in bone 
resorption (Gowen et al., 1999; Saftig et al., 1998; Salminen-Mankonen et al., 2007; Stoch and 
Wagner, 2007). Cathepsin K is also involved in lung matrix homeostasis (Bühling et al., 
2004), dermal extracellular matrix homeostasis (Rünger et al., 2007), and atherosclerotic 
plaque remodeling (Guo et al., 2009). Circulating serum cathepsin K has been found to play 
a significant role in both prostate cancer and breast cancer related bone metastasis (Tomita 
et al., 2008; Valta et al., 2008).   
Cathepsin K has become an established drug target for osteoporosis (Deal, 2009; Stoch and 
Wagner, 2007; Vasiljeva et al., 2007) . Two cathepsin K inhibitors have progressed to Phase II 
and Phase III clinical trials for osteoporosis. Ono’s ONO-5334 (Eastell et al., 2011; Manako, 
2011) is in Phase II while Merck’s odanacatib (Pérez-Castrillón et al., 2010) is in Phase III 
clinical trials.  
Cathepsin K has also been found to play roles in atherosclerosis (Guo et al., 2009), 
inflammation (Asagiri et al., 2008; Lecaille et al., 2008), and obesity (Podgorski et al., 2007; 
Yang et al., 2008). These findings suggested that cathepsin K may be one of the common 
biological links connecting low bone density to cardiovascular disease (Lutgens et al., 2007; 
Podgorski, 2009; Podgorski et al., 2007). Thus pointing to possible future anti-cathepsin K 
drug applications toward dual therapy for skeletal disease and atherosclerosis (Podgorski, 
2009) 
1.3 Research objectives 
Specific proteinase inhibitors are useful in investigations of the mechanisms and pathways 
of intracellular protein degradation and could lead to the development of therapeutic agents 
for treatment of many types of carcinomas, skeletal disease and atherosclerosis,  as well as 
Alzheimer's Disease. In the present communication, we report the successful production of 
functional human recombinant cathepsin B and K. The active enzymes have been used 
successfully in screening flavonoids for effective inhibitors against human cathepsins B and 
K enzymes. 
2. Experimental 
2.1 Materials 
E. coli strains JM109 and BL21(DE3)pLysS were used as host cells. The pET-15b was used for 
the expression vector. Antibiotics ampicillin and chloramphenicol were purchased from 
Sigma and Fisher Scientific, respectively. Yeast extract and bactotryptone were from BD 
Biosciences. Isopropyl thio-β-galactoside (IPTG) was from Calbiochem. FideliTaqTM PCR 
master mix was from United States Biochemical Corp and PCR master mix (2x) from 
Promega corporation. XhoI, alkaline phosphatase, and T4 DNA ligase were from New 
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England Biolabs. HisTrap FF column was from GE Healthcare. Z-Phe-Arg-pNA 
(Carbobenzoxycarbonyl-L-Phenylalanyl-L-Arginine para-nitroanilide) was from Enzo Life 
Sciences. Oligonucleotides were synthesized by Integrated DNA Technology. Glutathione 
(reduced) and GSSG (oxidized) were from Sigma–Aldrich. Precision Plus Protein 
Kaleidoscope Standards were from Bio-Rad Laboratories. 
2.2 Subcloning of recombinant human procathepsin B and K  
Full-length cDNA encoding of the human pre-pro-cathepsin B (GenBank accession number 
BC095408) and the human pre-pro-cathepsin K (GenBank accession number BC016058) were 
purchased from Open Biosystems. Plasmid DNA isolated from each clone was used as 
templates for amplification of coding region of procathepsin B and K (excluding signal 
peptide) using gene-specific primer pairs (see Table 1). Each primer was appended with 
XhoI restriction enzyme recognition site (underlined) to facilitate cloning. The XhoI 
restriction site was chosen because both cathepsin genes lack XhoI recognition site. The extra 
six nucleotides (selected at random) at the 5‘end of each primer were to facilitate cleavage 
by restriction enzymes.  
 
 Primers 
ProCatB forward primer ATA TAA CTC GAG CGG AGC AGG CCC TCT TTC C  
ProCatB reverse primer 
ATA TAA CTC GAG TTA GAT CTT TTC CCA GTA CTG 
ATC GGT G  
ProCatK forward primer ATG CGA CTC GAG CTG TAC CCT GAG GAG ATA CTG G 
ProCatK reverse primer ATG CGA CTC GAG TCA CAT CTT GGG GAA GCT GG 
Table 1. Synthetic primers for amplification of coding sequences of procathepsin B and K.   
Each PCR solution (50 μl) consisted of 25 μl FideliTaqTM PCR Master Mix (2x), 1 μM of 
each forward and reverse primer, and 10 ng plasmid template. The reaction was pre-
denatured at 94 oC for 5 min. Then 25 cycles were conducted, which consisted of 
denaturation at 94 oC for 45 sec, annealing at 55±10 oC for 45 sec, and extension at 68 oC 
for 1.5 min. A final extension was done at 68 oC for 10 min. The cycling process was 
accomplished by the Eppendorf Mastercycler. The PCR amplified DNA fragments were 
extracted once with equal volume of phenol/chloroform (1/1), once with 
chloroform/isoamyl alcohol (24/1), and DNA precipitated with ethanol (Sambrook and 
Russell, 2001). Each PCR fragments of procathepsin B or K was digested with XhoI to 
generate sticky ends and the digested products were separated on a 1.2% agarose gel. The 
desired bands were purified from agarose gel slice (Kim, 1992) and ligated to pET-15b 
which had been treated with XhoI and alkaline phosphatase. Each ligation reaction was 
then transformed into JM109 competent cells according to the method of Chung et al. 
(Chung et al., 1989) and plated on ampicillin containing plates. The transformants were 
screened to find recombinant DNA containing colonies by Quick Screening (Huang et al., 
2004). In Quick Screening, a toothpick was used to isolate a colony and the cells were 
resuspended in 25 μl of STE solution (100 mM NaCl, 20 mM Tris–Cl pH 7.5, and 10 mM 
EDTA). The suspension was extracted with phenol/chloroform and the aqueous layer 
was analyzed on a 1% agarose gel. The chimeric DNA (with DNA insert) migrates slower 
than the vector alone. The selected chimeric plasmids were isolated using boiling method 
(Sambrook and Russell, 2001).  
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The orientation of the insert in the chimeric plasmids was checked by PCR using the pET 5' 
sequencing primer and the gene specific reverse primer. Promega’s 2x PCR master mix was 
used because proofreading was not required in this case. PCR products are expected only 
for clones harboring an insert in the correct orientation. The correct recombinant plasmids 
(confirmed by DNA sequencing) were each transformed into BL21(DE3)pLysS host cells for 
protein expression.  
2.3 Overexpression of recombinant human procathepsin B and K 
The chosen transformants of BL21(DE3)pLysS harbored the chimeric plasmid (procathepsin B 
or K) in the correct orientation and reading frame was induced for protein expression in the 
presence of IPTG. Several growth conditions (varying growth media, induction temperatures, 
induction time, and inducer concentration) were tested and the one yielded the best results is 
described below. Each clone was grown in 10 mL terrific broth  (1.2 % bacto-tryptone, 2.4 % 
bacto-yeast extract, 0.4 % glycerol, 0.017 M KH2PO4 and 0.072 M K2HPO4) containing 100 
µg/ml ampicillin and 20 µg/ml chloramphenicol overnight on a shaker at 37 oC. Next day, the 
culture was diluted 1:20 in terrific broth containing ampicillin and chloramphenicol in a 
baffled Erlenmeyer flask. The culture was grown until A600 reached 0.8–1.2. At this point IPTG 
inducer was added to a final concentration of 0.5 mM along with 25% fresh terrific broth. The 
incubation temperature was dropped to 25 oC and cells were harvested 4-16 hours after IPTG 
induction. Overexpression of the target protein was checked by comparing total protein 
patterns before and after IPTG induction by SDS-PAGE.  
2.4 Purification of recombinant procathepsin B  
Recombinant procathepsin B was obtained from purified inclusion bodies of IPTG induced cells 
by a procedure described by Kuhej, et al, 1995 with minor modifications. The IPTG induced cell 
pellet (4.6 g from 500 mL culture) was re-suspended in 46 mL of 50 mM Tris-HCl, pH 8.0 
containing 5 mM EDTA and 5% sucrose, and was sonicated. The homogenate was divided into 
two centrifuge tubes and centrifuged at 6,000 x g for 10 min. The pellets containing inclusion 
body were washed twice by homogenizing each in 15 mL of 50 mM Tris-HCl, pH 8.0 containing 
5 mM EDTA and 0.1% Triton X-100 using a generator sawtooth followed by centrifugation at 
6,000 x g for 10 min at 4 °C. Each inclusion body pellet was consecutively washed twice with 10 
-15 mL of 50 mM Tris-HCl, pH 8.0 containing 5 mM EDTA and 2 M Urea.  The content was 
centrifuged as before. The purified inclusion bodies were solubilized in approximately 10 mL of 
8 M Urea/0.1 M Tris-HCl, pH 8.0/10 mM DTT by stirring for 1.5 h at room temperature. The 
protein concentration was approximately 10.8 mg/mL.  
The procathepsin B in the solubilized inclusion body was refolded and re-oxidized by 
dilution and dialysis according to a reported procedure (Kuhelj et al., 1995) with minor 
modification. An aliquot of the solubilized inclusion body was diluted to approximately 30 
μg/mL with 8 M urea in 0.1 M Tris-HCl, pH 8.0 containing 10 mM DTT and dialyzed 
against 4 L of 0.1 M sodium phosphate pH 7.0 containing 5 mM EDTA and 5 mM L-Cysteine 
overnight. (It took about 2 hours of occasional stirring with a glass rod to diffuse some urea 
so that the dialysis tubing could float). Dialysis was then carried out for approximately 24 
hours. Fresh buffer was changed once during dialysis. The dialyzed procathepsin B solution 
was collected and centrifuged at 10,000 x g for 10 min to remove precipitated protein. The 
protein was stored at -70 oC until use. Protein purification progress and purity were checked 
by 12% SDS-PAGE.  
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2.5 Activation of the procathepsin B  
Procathepsin B was autoactivated to its mature cathepsin B form by lowering the pH to 3.6 
(Kuhelj et al., 1995) with 1 M formic acid. The reaction was terminated by increasing the pH 
to 6 with addition of 1 M sodium phosphate pH 6.0. The autoactivation was carried out at 
4°C for various time intervals. The successful activation/cleavage was monitored by 
cathepsin B activity assay and 15% SDS-PAGE analysis.   
2.6 Activity assay of cathepsin B  
Cathepsin B was assayed using chromogenic substrate, Z-Phe-Arg-ρNA. The reaction consisted 
of 20 mM sodium acetate, pH 5.0, 1 mM EDTA, 5 mM L-Cysteine, 0.9-1.8 μg/mL cathepsin B, 
and 0.015-0.6 mM Z-Phe-Arg-ρNA in a total volume of 500 μl. The release of the para-
nitroaniline (ρNA) chromophore was monitored at 405 nm at 25 °C for 3 min, and the reaction 
rate was calculated from the slope of the trace showing the increase in absorbance over time. 
2.7 Purification of recombinant procathepsin K  
The recombinant procathepsin K was purified from IPTG induced E. coli cells according to a 
procedure reported by Hwang and Chung (Hwang and Chung, 2002) with slight 
modifications. Briefly, the cell pellet (from 250 mL culture) was sonicated in 25 mL of buffer 
A (50 mM Tris-HCl, pH 8.0, 0.5 M NaCl). The homogenate was centrifuged at 10,000 g for 20 
minutes at 4 °C. The pellet (containing inclusion body) was washed in buffer A plus 2 M 
urea. The content was centrifuged at 10,000 g for 20 minutes at 4 °C. The pellet was re-
suspended in 12.5 mL of buffer B (50 mM Tris-HCl, pH 8.0, 0.5 M NaCl, 6 M guanidine 
hydrochloride, 5 mM imidazole) to solubilize the inclusion body. The suspension was 
homogenized using a generator sawtooth and stirred at 4 °C for 1 hour. This was 
centrifuged at 10,000 g for 30 minutes. The supernatant was filtered using a 0.8 µM syringe 
filter. The filtrate (approximately 12 mL) was loaded onto a Ni column (5 mL HisTrapTM FF 
from GE Healthcare) that had been equilibrated with buffer B. The column was washed with 
buffer B until A280 reached baseline. The bound protein was eluted with buffer B plus 1 M 
imidazole and ten 1.3 mL fractions were collected. Protein assay was performed using Bio-
Rad protein binding assay. Fractions #4 and #5 which contained the most protein were used 
in refolding. The purified procathepsin K was observed on 12 % SDS-PAGE.    
2.8 Refolding and activation of recombinant procathepsin K 
The refolding of procathepsin K was performed by dilution and dialysis (Hwang and 
Chung, 2002). The eluted protein (2 mL) in guanidine-HCl was diluted in 100 mL of 
refolding buffer A (5 mM EDTA, 10 mM GSH, 1 mM GSSG, 0.7 M L-Arg, 1 % CHAPS). The 
dilution was achieved by adding the denatured protein drop by drop at 1 mL/minute into 
the refolding buffer followed by stirring overnight at 4 °C. The content was dialyzed 
(MWCO 8,000 – 14,000) against 4 L of 25 mM Tris-HCl, pH 8.0, 0.5 M NaCl overnight at 4 
°C. Fresh buffer was changed once during dialysis. Dialyzed protein was clarified by 
centrifugation and then concentrated using Vivaspin 20 with MWCO 10,000. The volume 
was reduced to one third of the original volume.  The procathepsin K protein was then 
activated in 0.2 M sodium acetate, pH 4.0, 5 mM DTT, 5 mM EDTA, and porcine pepsin (20 
μg/mL). The progress of activation was monitored by activity assay and 15% SDS-PAGE. 
Activation was terminated by raising the pH to 5.5 with addition of sodium acetate (pH 5.5) 
to 0.1 M as pepsin is inactive at this pH (Tauber and Kleiner, 1934). 
www.intechopen.com
Subcloning and Expression of Functional Human  
Cathepsin B and K in E. coli: Characterization and Inhibition by Flavonoids 
 
43 
2.9 Cathepsin K activity assay 
Cathepsin K was assayed using chromogenic substrate, Z-Phe-Arg-ρNA. The reaction 
mixture consisted of 100 mM sodium acetate buffer, pH 5.5, 2.5 mM EDTA, 2.5 mM DTT, 
various amounts of Z-Phe-Arg-ρNA, and appropriate amount of mature cathepsin K in a 
total volume of 500 μl using a procedure reported by Hwang and Chung  (Hwang and 
Chung, 2002) with minor modifications. The release of the ρNA chromophore was 
monitored at 405 nm at 25 °C for 3 min, and the reaction rate was calculated from the slope 
of the trace showing the increase in absorbance over time. 
2.10 Inhibition of active cathepsin B and K with flavonoids 
Amentoflavones have been shown to inhibit cathepsin B and K (Pan et al., 2005; Zeng et al., 
2006). Therefore, several different commercially available flavonoids were utilized, 
including baicalin, ametoflavone, celastrol, fisetin, kaempferol, luteolin, rutin, limonin, 
myricetin, and apigenin. Each flavonoid was tested for its activity as cathepsin B or K 
inhibitors. The enzyme reaction was monitored for three minute intervals by 
spectrophotometic assay at 405 nm using the chromogenic substrate described above. 
3. Results and discussion 
3.1 Subcloning of human procathepsin B and K 
The full-length human cDNA clone encoding cathepsin B purchased from Open Biosystems 
was in pBluescriptR vector and the cathepsin K cDNA was in pOTB7 vector. Each of the 
procathepsin B or K genes was amplified by PCR as described in the Experimental section. The 
PCR products were analyzed by 1% agarose gel (Figure 1).  The reaction worked well at all 
three annealing temperatures (57.1 oC, 54.4 oC, 51.7 oC for procathepsin B and 54.4 oC, 51.7 oC, 
49.3 oC for procathepsin K) as a strong band of about 900 bp was observed in every lane.   
 
 
Fig. 1. Agarose gel electrophoresis of PCR products of procathepsin B and K DNA inserts.  The 
plasmid pBluescriptR containing human cathepsin B cDNA was used as template and gene 
specific primer pair shown in Table 1 to amplify procathepsin B gene. Similarly, the plasmid 
pOTB7 containing human cathepsin K cDNA was used as template and its gene specific primer 
pair to amplified procathepsin K gene. PCR cycles were described in the Experimental section.  
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The XhoI-treated procathepsin B and K fragment from each gel was purified, inserted into 
the expression vector pET-15b, and transformed into JM109 competent cells. Transformants 
were treated with ampicillin to induce ampicillin resistance. All transformants were 
screened for the presence of a chimeric plasmid by the quick screening method as described 
in the Experimental. Since the cDNA was inserted into the vector at a single restriction site, 
XhoI, ligation of the insert is possible in either orientation.  Only the chimeric plasmid that 
contains the procathepsin B or K cDNA insert in the correct orientation is useful. Therefore, 
several insert-containing clones were checked for the orientation of the insert by PCR. 
Plasmids isolated by boiling method from each selected colony were used as template in the 
PCR. When the insert is in the correct orientation, a PCR product of about 1050 bp appears 
with pET 5’ primer and procat B or K reverse primer (Figure 2). This PCR product cannot be 
formed unless the insert is in the correct orientation. A positive PCR control was included 
using Forward and Reverse primer pair of procatB or K which yields about a 900 bp PCR 
product regardless of the insert orientation. Clones 3, 12 and 13 of procathepsin B 
candidates appeared to contain the DNA insert in the correct orientation, while clone 5 
contained a deletion and clones 1 and 14 contained the DNA insert in the wrong orientation 
(Figure 2 left panel). Clones 6, 7, 11, 12, 14 and 15 of procathepsin K candidates appeared to 
contain the DNA insert in the correct orientation, while clones 8, 10 and 13 had the DNA 
insert in the wrong orientation (Figure 2 right panel).  
 
 
Fig. 2. Orientation check of putative pET-15b-procat B and K clones by PCR. Template used: 
isolated plasmids from clones #1, 3, 5, 12, 13, and 14 of procatB candidates; isolated 
plasmids from clones #6, 7, 8, 10, 11, 12, 13, 14, and 15 of procatK candidates. Primers used: 
for the PCR control, procatB or K forward and reverse primer pairs were used; for procatB 
candidate clones pET 5’ primer and procatB reverse primer were used; for procatK 
candidate clones pET 5’ primer and procatK reverse primer were used. Promega’s 2x PCR 
mix was used. PCR cycles were described in the Experimental section.  
3.2 Overexpression of recombinant procathepsin B and K 
The chimeric plasmids with DNA inserts in the correct orientation and correct reading 
frame were transformed into BL21(DE3)pLysS for protein expression. Overexpression of the 
procathepsin B had been achieved according to the SDS-PAGE which showed 
overexpression of the proenzyme at about 35 kDa (Figure 3. left panel). Expression level of 
the recombinant procathepsin B after 4 h IPTG induction was greater than 40% of total 
bacterial protein and the procathepsin B level remained high after overnight induction.  
Overexpression of the recombinant procathepsin K was clearly visible after 4 h IPTG 
induction and the expression level increased with increasing induction time up to 22 hours 
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(Figure 3. Right panel). The recombinant procathepsin K showed an approximate molecular 
weight of 38 kD on SDS-PAGE gel. 
3.3 Purification of recombinant procathepsin B and K 
3.3.1 Purification of recombinant procathepsin B  
The recombinant procathepsin B was expressed largely as insoluble inclusion bodies as very 
little procathepsin B was found in the soluble protein fraction (Figure 4. lane 3). 
Procathepsin B was purified from the inclusion bodies as described in the Experimental 
section. The progress of purification was monitored by SDS-PAGE (Figure 4). As shown in 
Figure. 4 lane 4, the inclusion bodies contained greater than 90% of procathepsin B. Overall 
yield of the procathepsin B enzyme was about 1.5 mg per 100 ml of bacterial culture. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3. SDS-PAGE showing induction progress of recombinant procathepsin B and K after 
IPTG addition. BL21 (DE3)pLysS cells containing pET-15b-procathepsin B or pET-15b-
procathepsin K were cultured and protein expression induced by IPTG as described in the 
Experimental section. An aliquot of each culture was collected at various time intervals after 
IPTG addition. The cells were lysed in SDS-PAGE loading buffer by repeated vortexing and 
heating. The cell lysate was analyzed by 12% SDS-PAGE. 
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Fig. 4. SDS-PAGE showing the progress of purification of procathepsin B. The gel contained 
12% acrylamide. Lane 1: Precision Plus Protein Kaleidoscope Standards; lane 2: Total IPTG 
induced E. coli cell lysate; Lane 3: Soluble proteins in the cell-free extract; Lane 4: Crude 
inclusion bodies before being subjected to washes; Lanes 5 & 6: First and second washes of 
the inclusion bodies with 50 mM Tris-HCl pH 8.0 containing 5 mM EDTA and 0.1% Triton 
X-100; lane 7 & 8: First and second washes of the inclusion bodies with 50 mM Tris-HCl, pH 
8.0 containing 5 mM EDTA and 2 M Urea; Lane 9: Purified and refolded procathepsin B. 
3.3.2 Purification of recombinant procathepsin K  
The procathepsin K was also expressed as insoluble proteins in inclusion bodies as the 
procathepsin K band was missing from the soluble protein fraction (Figure. 5. lane 5). His-
tagged procathepsin K protein was purified from the solubilized inclusion bodies by affinity 
chromatography on a HisTrapTM FF column to near homogeneity. The protein was then 
refolded and concentrated (Figure. 5 lane 7). Overall yield of the procathepsin K enzyme 
was about 1 mg per 100 ml of bacterial culture. 
 
 
Fig. 5. SDS-PAGE showing overexpression of the human procathepsin K and the purification 
process. The gel contained 12% acrylamide. Lane 1: Precision Plus Protein Kaleidoscope 
Standards; lane 2: total lysate of the uninduced cells; lane 3: total lysate of 8 hours IPTG induced 
cells; lane 4: homogenate of the IPTG induced sample; lane 5: soluble proteins in cell-free extract 
of the IPTG induced sample; lane 6: Ni column wash; lane 7: purified procathepsin K. 
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3.4 Activation of the procathepsin B and K proteins 
3.4.1 Activation of procathepsin B and functional cathepsin B assay 
The recombinant procathepsin B activation was carried out by autoactivation as described in 
the Experimental section. The success of the activation was demonstrated by the cathepsin B 
activity assay and SDS-PAGE. As observed in the SDS-PAGE (Figure 6) clear bands are 
observed and the proteolytic cleavage was evident (lane 2). 
The cathepsin B activity was demonstrated by its ability to cleave the Z-Phe-Arg-ρNA. 
These results show a linear relationship between the formation ρNA products with 
increasing cathepsin B levels from 0.024 to 0.19 μM (Figure 7).  
 
 
Fig. 6. SDS-PAGE showing autoactivation of procathepsin B. The gel contained 15% 
acrylamide. Lane 1: purified procathepsin B protein; Lane 2: autoactivated cathepsin B protein. 
 
 
Fig. 7. Cathepsin B demonstrated enzyme concentration-dependent activity. The product 
formation linearity was verified by the use of increasing amounts of cathepsin B from 0.024 
to 0.19 µM. The activity was assayed using a chromogenic substrate, Z-Phe-Arg-ρNA, and 
the rate was monitored by the increase in absorption at 405 nm due to the release of the 
ρNA chromophore. 
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3.4.2 Activation of procathepsin K and functional cathepsin K assay 
The refolded procathepsin K protein was activated to mature cathepsin K with the aid of 
porcine pepsin. Figure 8 shows successful cleavage of the procathepsin K (~38 kDa) into 2 
fragments: mature cathepsin K (~26.5 kDa) and propeptide fragment (~11.5 kDa).  
 
 
Fig. 8. SDS-PAGE showing activation of procathepsin K with pepsin. The gel contained 15% 
acrylamide. Lane 0: procathepsin K untreated; Lane 1: procathepsin K treated with pepsin for 1 
hr. After 1 hr of pepsin activation, the procathepsin K (~38 kDa) was successfully cleaved into 
2 fragments: mature cathepsin K (~26.5 kDa) and propeptide fragment (~11.5 kDa). 
The cathepsin K activity is demonstrated by its ability to cleave the Z-Phe-Arg-ρNA. The 
results show a linear relationship between the formation ρNA chromophore product with 
increasing cathepsin K levels from 0.09 to 0.72 μM (Figure 9).  
 
 
Fig. 9. Cathepsin K demonstrated enzyme concentration-dependent activity. The product 
formation linearity was verified  by the use of increasing amounts of cathepsin K from 0.09 
to 0.72 μM. The activity was assayed spectrophotometrically by monitoring the increase in 
absorption at 405 nm as described in the text. 
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3.5 Screening of flavonoid inhibitors of cathepsin B and K  
Flavonoids, polyphenolic compounds predominantly found in colorful fruits and 
vegetables, have been regarded of as possessing “antiviral, anti-allergic, antiplatelet, anti-
inflammatory, antitumor, and antioxidant (Arora et al., 1998; Rice-Evans and Miller, 1996)” 
properties. Flavonoids have been known to have anti-cancer effects and could potentially 
inhibit cathepsin B. In particular, amentoflavones have been shown to inhibit cathepsin B 
and K (Pan et al., 2005; Zeng et al., 2006). Therefore a search for other flavonoid inhibitors of 
cathepsins was undertaken. Several commercially available flavonoids were tested 
(amentoflavone, apigenin, baicalin, celastrol, fisetin, kaempferol, limonin, luteolin, 
myricetin, and rutin), for their ability to inhibit cathepsin B or K. The inhibition of cathepsin 
B activity by each of the flavonoid at 40 μM is shown in Figure 10. Ametoflavone, celastrol, 
and luteolin demonstrated the best flavonoid inhibitors of cathepsin B of those screened. 
The IC50 value for celastrol was 125 μM. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 10. Inhibition data of cathepsin B by flavonoids. Cathepsin B was incubated with 40 µM 
flavonoid. The residual activity was determined using chromogenic substrate, Z-Phe-Arg-
ρNA. The enzymatic reaction was monitored by the increase in absorption at 405 nm due to 
the release of the ρNA chromophore. 
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Most of these flavonoids were also screened for their inhibition of cathepsin K activity 
(Figure 11). Results show that apigenin, celastrol, and myricetin are among the strongest 
inhibitors of cathepsin K of those tested. Their IC50 values of the cathepsin K inhibitors were 
determined to be 8.7 µM, 135.5 µM, and 100.5 µM for apigenin, celastrol, and myricetin, 
respectively.  
 
 
Fig. 11. Inhibition data of cathepsin K by flavonoids. Cathepsin K was incubated with 40 µM 
flavonoid. The residual enzyme activity was determined using chromogenic substrate, Z-
Phe-Arg-ρNA, by monitoring the increase in absorption at 405 nm due to the release of the 
ρNA chromophore. 
4. Conclusion  
In conclusion, the subcloning, expression, and purification of recombinant procathepsins 
B and K has been accomplished. Each of the proenzyme has been activated and shown to 
be functional as demonstrated by the enzyme’s ability to cleave the chromogenic 
substrate, Z-Phe-Arg-ρNA. The enzymes have been used successfully to screen potent 
flavonoid inhibitors. The availability of substantial amounts of active cathepsin B and K 
will greatly facilitate the identification of small molecule inhibitors. The information 
obtained from studies such as this will greatly facilitate drug discovery programs in the 
efforts to develop effective therapies for osteoporosis, cancer, and Alzheimer’s Disease.  
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